Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
European Respiratory Journal · 2023
DOI: 10.1183/13993003.01596-2022 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Fajri Gafar und 59 weiteren Autor:innen. Beteiligte Einrichtung: University of Groningen, Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen, The Netherlands …. Hauptthemen laut MEDLINE: Antitubercular Agents, Isoniazid. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council, NIAID NIH HHS, Wellcome Trust.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level.
Methods
We systematically searched MEDLINE, Embase and Web of Science (1990–2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration–time curve from 0 to 24 h post-dose (AUC 0–24 ) and peak plasma concentration ( C max ) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC 0–24 and C max were assessed with linear mixed-effects models.
Results
Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC 0–24 were summarised for isoniazid (18.7 (95% CI 15.5–22.6) h·mg·L −1 ), rifampicin (34.4 (95% CI 29.4–40.3) h·mg·L −1 ), pyrazinamide (375.0 (95% CI 339.9–413.7) h·mg·L −1 ) and ethambutol (8.0 (95% CI 6.4–10.0) h·mg·L −1 ). Our multivariate models indicated that younger age (especially
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Groningen, Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen, The Netherlands f.gafar@rug.nl.
- University of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.
- University of Cape Town, Institute of Infectious Disease and Molecular Medicine, Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Cape Town, South Africa.
- Radboud University Medical Center, Radboud Institute of Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands.
- Stellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.
- The Children's Hospital at Westmead, Sydney, Australia.
ORCID-Profile: Fajri Gafar, H Simon Schaaf, Ben J Marais, Chishala Chabala, Ephrem Engidawork, Anthony J Garcia-Prats, Diana Gibb, Stephen M Graham, Estomih Mduma, Stephanie Thee
Förderung
- Medical Research Council
- NIAID NIH HHS
- Wellcome Trust
- NICHD NIH HHS
- World Health Organization
- NCRR NIH HHS
- Lembaga Pengelola Dana Pendidikan
Zitieren
APA
Gafar, F., Wasmann, R. E., McIlleron, H. M., Aarnoutse, R. E., Schaaf, H. S., Marais, B. J., Agarwal, D., Antwi, S., Bang, N. D., Bekker, A., Bell, D. J., Chabala, C., Choo, L., Davies, G. R., Day, J. N., Dayal, R., Denti, P., Donald, P. R., Engidawork, E., …, & Yang, H. (2023). Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. European Respiratory Journal. https://doi.org/10.1183/13993003.01596-2022
Vancouver
Gafar F, Wasmann RE, McIlleron HM, Aarnoutse RE, Schaaf HS, Marais BJ, et al. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. European Respiratory Journal. 2023. doi:10.1183/13993003.01596-2022
BibTeX
@article{Gafar2023,
author = {Gafar, Fajri and Wasmann, Roeland E and McIlleron, Helen M and Aarnoutse, Rob E and Schaaf, H Simon and Marais, Ben J and Agarwal, Dipti and Antwi, Sampson and Bang, Nguyen D and Bekker, Adrie and Bell, David J and Chabala, Chishala and Choo, Louise and Davies, Geraint R and Day, Jeremy N and Dayal, Rajeshwar and Denti, Paolo and Donald, Peter R and Engidawork, Ephrem and Garcia-Prats, Anthony J and Gibb, Diana and Graham, Stephen M and Hesseling, Anneke C and Heysell, Scott K and Idris, Misgana I and Kabra, Sushil K and Kinikar, Aarti and Kumar, Agibothu K Hemanth and Kwara, Awewura and Lodha, Rakesh and Magis-Escurra, Cecile and Martinez, Nilza and Mathew, Binu S and Mave, Vidya and Mduma, Estomih and Mlotha-Mitole, Rachel and Mpagama, Stellah G and Mukherjee, Aparna and Nataprawira, Heda M and Peloquin, Charles A and Pouplin, Thomas and Ramachandran, Geetha and Ranjalkar, Jaya and Roy, Vandana and Ruslami, Rovina and Shah, Ira and Singh, Yatish and Sturkenboom, Marieke G G and Svensson, Elin M and Swaminathan, Soumya and Thatte, Urmila and Thee, Stephanie and Thomas, Tania A and Tikiso, Tjokosela and Touw, Daan J and Turkova, Anna and Velpandian, Thirumurthy and Verhagen, Lilly M and Winckler, Jana L and Yang, Hongmei},
title = {Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis},
journal = {European Respiratory Journal},
year = {2023},
doi = {10.1183/13993003.01596-2022}
}
EUVIMED